{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T00:20:37Z","timestamp":1719706837472},"reference-count":41,"publisher":"Baishideng Publishing Group Inc.","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>The benefits and risks of Xileisan (XLS) in the treatment of ulcerative colitis (UC) remain unclear.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>The present study aimed to evaluate the efficacy and safety of the combination of XLS and mesalazine when treating UC.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>We searched eight databases for clinical trials evaluating the combination of XLS and mesalazine in the treatment of UC, up to January 2024. Meta-analysis and trial sequential analysis (TSA) were performed using Revman 5.3 and TSA 0.9.5.10 beta, respectively.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>The present study included 13 clinical studies involving 990 patients, of which 501 patients received XLS combined with mesalazine while 489 patients received mesalazine alone. The meta-analysis showed that, in terms of efficacy, the combination of XLS and mesalazine significantly improved the clinical efficacy rate by 22% [risk ratio (RR) = 1.22; 95%CI: 1.15\u20131.28; P  &lt; 0.00001] and mucosal improvement rate by 25% (RR = 1.25; 95%CI: 1.12\u20131.39; P  = 0.0001), while significantly reducing the duration of abdominal pain by 2.25 days [mean difference (MD) = -2.25; 95%CI: -3.35 to -1.14; P  &lt; 0.0001], diarrhea by 2.06 days (MD = -2.06; 95%CI: -3.92 to -0.20; P  = 0.03), hematochezia by 2.32 days (MD = -2.32; 95%CI: -4.02 to -0.62; P  = 0.008), tumor necrosis factor alpha by 16.25 ng\/mL (MD = -16.25; 95%CI: -20.48 to -12.01; P  &lt; 0.00001), and interleukin-6 by 14.14 ng\/mL (MD = -14.14; 95%CI: -24.89 to -3.39; P  = 0.01). The TSA indicated conclusiveness in the meta-analysis of the efficacy endpoints. In terms of safety, the meta-analysis revealed that the combination of XLS and mesalazine did not increase the occurrence of total and gastrointestinal adverse events, abdominal distension, and erythema (P  &gt; 0.05). The TSA showed non conclusive findings in the meta-analysis of the safety endpoints. Harbord\u2019s test showed no publication bias (P  = 0.734).<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>Treatment with XLS alleviated the clinical symptoms, intestinal mucosal injury, and inflammatory response in patients with UC, while demonstrating good safety.<\/jats:p>","DOI":"10.12998\/wjcc.v12.i21.4703","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T06:02:46Z","timestamp":1719640966000},"page":"4703-4716","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis: A meta-analysis and trial sequential analysis"],"prefix":"10.12998","volume":"12","author":[{"given":"Xin-Yu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Ke","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian-Jun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60150-0"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i28.9458"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.07.002"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2022-000994"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-624"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220181"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0676-z"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.12.2"},{"key":"B9","unstructured":"Huang L, Liu TG, Chen B, Liu SY, Ma XY, He JZ, He Y, Gu XH. [Textual research on Xilei Powder]. Zhongguo Zhongyao Zazhi 2020; 45: 4262-4266"},{"key":"B10","unstructured":"Dai JP. [Study on the Mechanism and Effective Fractions of Xilei San to Promote Mucosal Ulcers Healing]. Jiangsu University 2012"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.11569\/wcjd.v16.i32.3700"},{"key":"B12","unstructured":"Wu KC, Liang J, Ran ZH, Qian JM, Yang H, Chen MH, He Y. [Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)]. Zhongguo Shiyong Neike Zazhi 2018; 38: 796-813"},{"key":"B13","unstructured":"Cai Y, He MJ, Luo PP. [Effect of Mesalamine combined with Tin Powder enema in the treatment of ulcerative colitis andits influence on the immune function and cytokines of patients]. Zhongguo Xiandai Yixue 2022; 29: 60-64"},{"key":"B14","unstructured":"Ding SY. [Clinical effects of retention enemas of Xilei San oxide combined with oral mesalazine in the treatment of ulcerative colitis]. Zhongguo Nongcun Weisheng 2019; 11: 60"},{"key":"B15","unstructured":"Ge YL, Wu H. [Clinical efficacy of mesalazine combined with Xi Lei Powder enema in the treatment of ulcerative colitis]. Haixia Yaoxue Zazhi 2011; 23: 114-115"},{"key":"B16","unstructured":"Li Y. [Efficacy of oral mesalazine combined with modified retention enemas of Xilei San in the treatment of ulcerative colitis in the elderly]. Jiankang Bidu 2017; 43: 168-170"},{"key":"B17","unstructured":"Liu WJ. [Clinical observation on 56 cases of ulcerative colitis treated by mesalazine enteric-coated tablets combined with Xileisan]. Yixue Luntan Zazhi 2015; 36: 150-151"},{"key":"B18","unstructured":"Ni GT, Chen SH. [Therapeutic efficacy of mesalazine combined with Xi Lei Powder in the treatment of ulcerative colitis]. Jiangxi Yixue Zazhi 2011; 46: 923-924"},{"key":"B19","unstructured":"Wang SP. [Clinical efficacy of mesalazine oral combined with Xilei San enema in the treatment of ulcerative colitis]. Guizhou Yixue Zazhi 2016; 40: 168-170"},{"key":"B20","unstructured":"Xu XQ, Wang XF. [Mesalazine combined with Xi Lei Powder enema in the treatment of ulcerative colitis in 84 cases]. Zhongguo Zhongyiyao Xinxi Zazhi 2010; 2: 168-169"},{"key":"B21","unstructured":"Yao ZG, Yang WW. [Clinical efficacy of Xilei San enema combined with mesalazine in the treatment of damp-heat ulcerative colitis and its effect on the disease activity index].  Zhongguo Chufangyao Zazhi 2022; 20: 138-140"},{"key":"B22","unstructured":"Zhang GY. [Thirty-five cases of ulcerative colitis treated with Xi Lei Powder combined with mesalazine enteric-coated tablets]. Zhongguo Zhiyao 2013; 22: 99"},{"key":"B23","unstructured":"Zhang ZF, Nie XZ. [Efficacy and adverse effects of retention enemas with Xilei Powder and mesalazine enteric-coated tablets in the treatment of ulcerative colitis]. Dangdai Yixue 2016; 22: 148-149"},{"key":"B24","unstructured":"Zhu HR. [The Clinical Efficacy for Enteric-coated Tablets Oral Mesalazine Joint Xileisan Retention Enema inthe Treatment of Ulcerative Colitis]. Zhongguo Yiyao Zhinan 2013; 11: 58-59"},{"key":"B25","unstructured":"Zhu Y, Xie HZ. [Effect of Xi Lei Powder enemas and Mesalazine for active ulcerative colitis]. Xinjiang Yike Daxue Xuebao 2009; 32: 1459-1461"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04234.x"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1771293"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2292768"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02704-0"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0080"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15159.1"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.2.99"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub5"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-3927"},{"key":"B35","unstructured":"Huang L, Wu Q, Cui RY, Tuo T, Xiao Y, Pan YS. [Progress in the study of the clinical expansion of the application of Xilei San]. Jichu Zhongyi Zazhi 2016; 22"},{"key":"B36","unstructured":"Xu F. [Curing Ulcerative Colitis with Chinese Herbal Binpeng Powder and Xilei Powder]. Jiangsu Zhongyiyao Zazhi 1964"},{"key":"B37","unstructured":"Sun XX. [Retention enema of a mixture of stannous and safranin in the treatment of ulcerative colitis]. Zhonguo Chuji Wiesheng Baojian 1988"},{"key":"B38","unstructured":"Wei R, Sun PL, Geng SG, Zhong YS. [Research progress of traditional Chinese medicine enema in the treatment of ulcerative colitis].  Hunan Zhongyiyao Zazhi 2019; 35: 149-151"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.08.003"},{"key":"B40","unstructured":"Song DX, He HQ, Zhang WL, Shao Q, Li YP. [Effects of chymotrypsin combined with xileisan on intestinal mucosal barrier in ulcerative colitisand study on its mechanism]. Zhongguo Zhongxiyi Jiehe Xiaohua Zazhi 2019; 27: 179-185"},{"key":"B41","unstructured":"Jia WP, Zhang Y, Ni J, Li X. [Effect of ileisan temperature-sensitive gels on endothelial nitric oxide synthase, vascularendothelial growth factor A and tumor necrosis factor-a expression in rats with bleeding internahemorrhoids]. Yufang Yixue 2023; 35: 27-31"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i21\/4703.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i21\/4703.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T06:05:17Z","timestamp":1719641117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i21\/4703.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":41,"journal-issue":{"issue":"21"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v12.i21.4703","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}